TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By The Schall Law Firm
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors for a class action lawsuit against Telix Pharmaceuticals Limited (NASDAQ: TLX) for securities fraud. The company allegedly made false and misleading statements regarding its prostate cancer therapeutic candidates and overstated its supply chain quality during the period of February 21, 2025 to August 28, 2025. Investors who suffered losses are encouraged to contact the firm before January 9, 2026.

Insights
RNMBY   positive

Listed as a key player in a market expected to expand with increasing defense modernization initiatives


TLX   negative

The company is accused of making false and misleading statements about its therapeutic candidates and supply chain quality, resulting in artificially inflated stock value and investor losses. These allegations of securities fraud and material misrepresentation are serious violations that negatively impact investor confidence and shareholder value.